Gregory M Weinhoff - Net Worth and Insider Trading

Gregory M Weinhoff Net Worth

The estimated net worth of Gregory M Weinhoff is at least $3 Million dollars as of 2024-10-16. Gregory M Weinhoff is the Chief Business Officer of Centessa Pharmaceuticals PLC and owns about 206,750 shares of Centessa Pharmaceuticals PLC (CNTA) stock worth over $3 Million. Details can be seen in Gregory M Weinhoff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gregory M Weinhoff has not made any transactions after 2024-09-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Gregory M Weinhoff

Gregory M Weinhoff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gregory M Weinhoff owns 3 companies in total, including Sio Gene Therapies Inc (SIOX) , Amicus Therapeutics Inc (FOLD) , and Centessa Pharmaceuticals PLC (CNTA) .

Click here to see the complete history of Gregory M Weinhoff’s form 4 insider trades.

Insider Ownership Summary of Gregory M Weinhoff

Ticker	Comapny	Transaction Date	Type of Owner
SIOX	Sio Gene Therapies Inc	2015-08-12	Principal Financial Officer
FOLD	Amicus Therapeutics Inc	2007-05-30	director & 10 percent owner
CNTA	Centessa Pharmaceuticals PLC	2024-09-25	Chief Financial Officer

Gregory M Weinhoff Latest Holdings Summary

Gregory M Weinhoff currently owns a total of 1 stock. Gregory M Weinhoff owns 206,750 shares of Centessa Pharmaceuticals PLC (CNTA) as of September 25, 2024, with a value of $3 Million.

Latest Holdings of Gregory M Weinhoff

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CNTA	Centessa Pharmaceuticals PLC	2024-09-25	206,750	16.09	3,326,608

Holding Weightings of Gregory M Weinhoff

Gregory M Weinhoff Form 4 Trading Tracker

According to the SEC Form 4 filings, Gregory M Weinhoff has made a total of 5 transactions in Centessa Pharmaceuticals PLC (CNTA) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Centessa Pharmaceuticals PLC is the sale of 16,619 shares on September 25, 2024, which brought Gregory M Weinhoff around $260,752.

Insider Trading History of Gregory M Weinhoff

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gregory M Weinhoff Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Gregory M Weinhoff Ownership Network

Ownership Network List of Gregory M Weinhoff

No Data

Ownership Network Relation of Gregory M Weinhoff

Gregory M Weinhoff Owned Company Details

What does Sio Gene Therapies Inc do?

Who are the key executives at Sio Gene Therapies Inc?

Gregory M Weinhoff is the Principal Financial Officer of Sio Gene Therapies Inc. Other key executives at Sio Gene Therapies Inc include Chief Commercial Officer Parag V Meswani , Chief Executive Officer Pavan Cheruvu , and 10 percent owner Roivant Sciences Ltd. .

Sio Gene Therapies Inc (SIOX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sio Gene Therapies Inc (SIOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sio Gene Therapies Inc (SIOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sio Gene Therapies Inc (SIOX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sio Gene Therapies Inc Insider Transactions

No Available Data

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

Gregory M Weinhoff is the director & 10 percent owner of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, Gregory M Weinhoff made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 345,323 shares made by John F Crowley , a net sale of 229,061 shares made by Bradley L Campbell , and a net sale of 95,000 shares made by Ellen Rosenberg .

In summary, during the past 3 months, insiders sold 22,500 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 22,500 shares. During the past 18 months, 812,168 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 812,168 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amicus Therapeutics Inc Insider Transactions

No Available Data

What does Centessa Pharmaceuticals PLC do?

Who are the key executives at Centessa Pharmaceuticals PLC?

Gregory M Weinhoff is the Chief Financial Officer of Centessa Pharmaceuticals PLC. Other key executives at Centessa Pharmaceuticals PLC include director & Chief Executive Officer Saurabh Saha , Chief People Officer Karen M. Anderson , and SVP Regulatory Affairs Harris Rotman .

Centessa Pharmaceuticals PLC (CNTA) Insider Trades Summary

Over the past 18 months, Gregory M Weinhoff made 4 insider transaction in Centessa Pharmaceuticals PLC (CNTA) with a net sale of 101,619. Other recent insider transactions involving Centessa Pharmaceuticals PLC (CNTA) include a net sale of 285,000 shares made by Saurabh Saha , a net sale of 41,751 shares made by Harris Rotman , and a net sale of 13,300 shares made by Antoine Yver .

In summary, during the past 3 months, insiders sold 386,619 shares of Centessa Pharmaceuticals PLC (CNTA) in total and bought 0 shares, with a net sale of 386,619 shares. During the past 18 months, 500,830 shares of Centessa Pharmaceuticals PLC (CNTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 500,830 shares.

Centessa Pharmaceuticals PLC (CNTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Centessa Pharmaceuticals PLC Insider Transactions

No Available Data

Gregory M Weinhoff Mailing Address

Above is the net worth, insider trading, and ownership report for Gregory M Weinhoff. You might contact Gregory M Weinhoff via mailing address: C/o Centessa Pharmaceuticals Plc, 3rd Fl., 1 Ashley Rd, Altrincham, Cheshire X0 Wa14 2dt.

Discussions on Gregory M Weinhoff

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.